Early Prediction Model for Etoposide-Based Protocols Resistance in Pediatric HLH
{{output}}
Background: Etoposide-based protocols remain the first-line therapy for pediatric hemophagocytic lymphohistiocytosis (HLH), yet 20-30% of patients exhibit primary resistance. Early identification of non-responders is critical to ... ...
